August 30th 2024
The phase 3 KEYNOTE-867 and KEYNOTE-630 studies will be stopped due to futility, following analysis from independent data monitoring committees.
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Annual Hawaii Cancer Conference
January 25-26, 2025
Register Now!
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Differentiating Adverse Events for Antibody-Drug Conjugates Across Solid Tumor Management
View More
FDA Clears Lazertinib/Amivantamab for First-Line EGFR-Mutated NSCLC
August 20th 2024Lazertinib and amivantamab as a first-line treatment for patients with locally advanced or metastatic non–small cell lung cancer with specific EGFR mutations demonstrated superior efficacy compared with standard treatment.
Read More
FDA Lifts Partial Clinical Hold on Phase 1 YL202 Trial in NSCLC and Breast Cancer
August 19th 2024The FDA has lifted the partial clinical hold on the phase 1 YL202-INT-101-01 trial, allowing enrollment to resume in the US for patients with advanced NSCLC harboring EGFR mutations and HR-positive/HER2-negative breast cancer.
Read More
Quaratusugene Ozeplasmid Shows Early Efficacy in 2 Lung Cancer Trials
August 14th 2024In the Acclaim-1 and Acclaim-3 trials, prolonged progression-free survival and partial remission were observed with quaratusugene ozeplasmid plus osimertinib and atezolizumab for advanced lung cancer treatment.
Read More
AFFINITY Study Completes Enrollment for Novel Aliya PEF System in Advanced Lung Cancer
August 9th 2024The AFFINITY study has finished enrolling participants to evaluate the Aliya pulsed electric field system in patients with stage IV non–small cell lung cancer or lung metastases who are not candidates for surgery.
Read More
Osimertinib Offers New Standard of Care in Stage III EGFR-Mutated NSCLC
August 6th 2024Suresh S. Ramalingam, MD, discussed the practice-changing findings and implications of the phase 3 LAURA study investigating osimertinib for the treatment of patients with EGFR-mutated non–small cell lung cancer.
Read More
Participants Discuss Rare Dual Immunotherapy AE Experiences in NSCLC
August 5th 2024During a Case-Based Roundtable® event, John V. Heymach, MD, PhD, talked with event participants about adverse events they have observed in their patients after using immune checkpoint inhibitors in the second article of a 2-part series.
Read More
Subcutaneous Amivantamab Shows Promise in Treatment-Naive EGFR-Mutated NSCLC
August 1st 2024Nicolas Girard, MD, PhD, discussed findings from the PALOMA-2 study investigating subcutaneous vs intravenous amivantamab plus lazertinib for previously untreated, EGFR-mutant non–small cell lung cancer.
Read More
THIO Shows Lower Toxicity Than Standard Treatments in NSCLC Study
July 25th 2024A phase 2 trial shows that THIO, a new investigational drug, combined with cemiplimab, may be an effective and well-tolerated treatment for patients with advanced non–small cell lung cancer who have exhausted other options.
Read More
CNS Activity of Third-Generation ALK TKIs Influence Approach in NSCLC
June 21st 2024During a Case-Based Roundtable® event, Yasir Y. Elamin, MD, discussed with participants how they select treatment for a patient with ALK+ non–small cell lung cancer and brain metastases in the first article of a 2-part series.
Read More
TTFields Therapy Delays Intracranial Progression in NSCLC Brain Metastases
June 4th 2024The METIS trial of tumor treating fields for the treatment of brain metastases in patients with non–small cell lung cancer met its primary end point, showing a statistically significant improvement in time to intracranial progression.
Read More